endo-annual-gh-igf1-post-med-withdrawal-rt-efficacy

name	endo-annual-gh-igf1-post-med-withdrawal-rt-efficacy
description	Recommends annual GH and IGF-1 reassessment following medication withdrawal to assess the efficacy of radiation therapy in patients with acromegaly. Use during long-term follow-up after radiotherapy when evaluating biochemical control after a planned drug-free interval.

Annual GH/IGF-1 reassessment after medication withdrawal to monitor RT efficacy

STEP 1 — Gather Information

Document date and type of radiotherapy (conventional RT or SRT), current medical therapy (SRL, pegvisomant, dopamine agonist), and duration of medication withdrawal (e.g., ≥4 weeks for SRLs, ≥1–2 weeks for pegvisomant per guideline). Obtain baseline pre‑RT GH/IGF-1 if available, confirm patient is off medication for the required washout interval, and note any symptoms of hormone excess or deficiency.

STEP 2 — Rule In / Rule Out

Determine whether adequate medication withdrawal has been achieved. If the patient is still on active medical therapy or the washout period is insufficient, defer testing until off therapy for the appropriate interval. If withdrawal is complete, proceed to measure serum IGF-1 and GH (random or post‑glucose).

STEP 3 — Classify or Stratify

Interpret results using age‑normalized IGF-1 and a GH therapeutic goal of <1 µg/L (random or post‑glucose). Controlled: IGF-1 within age‑adjusted normal range and GH <1 µg/L. Uncontrolled: IGF-1 elevated above normal or GH ≥1 µg/L. Optionally stratify by degree of elevation (mild, moderate, severe) to guide next steps.

STEP 4 — Decide

If controlled, continue annual GH/IGF-1 monitoring to sustain RT efficacy assessment. If uncontrolled, obtain pituitary imaging (MRI preferred) to evaluate residual tumor, discuss therapeutic intensification (repeat medical therapy, consider re‑irradiation or surgery), and plan reassessment after any intervention.

Clinical Guardrails / Mimics / Pitfalls

Do not measure GH/IGF-1 while patient is on active medical therapy, as this will underestimate RT efficacy; avoid relying on random GH alone without IGF-1; use the same assay over time to minimize inter‑assay variability; be aware that estrogen therapy or pregnancy can lower IGF-1 and falsely suggest control; do not interpret transient GH spikes as lack of RT effect without confirmatory testing.

Concrete Clinical Example

A 48‑year‑old patient with acromegaly received SRT 2 years ago and was on pegvisomant 10 mg daily. Pegvisomant was stopped for 1 week; IGF-1 measured age‑normalized normal, random GH 0.9 µg/L. Interpretation: RT effective. Schedule annual GH/IGF-1 reassessment.

Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700